MASLD or MetALD? Unveiling the Role of Alcohol in Liver Disease Progression in Diabetic Patients
Authors:
- Ermina StratinaESErmina Stratina
- Carol StanciuCSCarol Stanciu
- Robert NastasaRNRobert Nastasa
- Sebastian ZenoviaSZSebastian Zenovia
- Remus StafieRSRemus Stafie
- Adrian RotaruARAdrian Rotaru
- Stefan ChiriacSCStefan Chiriac
- Irina GirleanuIrina Girleanu
- Cristina MuzicaCristina Muzica
- Horia MineaHMHoria Minea
- Laura HuibanLHLaura Huiban
- Anca TrifanAnca Trifan
Open Access
- 31 December 2025
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 14 (1) , 82
Abstract
Background: The transition from the term non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD), an umbrella term for several related conditions, offers benefits, particularly in identifying cardiometabolic risk factors more effectively. However, the impact of alcohol consumption on liver disease progression remains significant, leading to the recognition of a new entity: MetALD (metabolic dysfunction-associated steatotic liver disease with moderate alcohol intake). Aim: This study aimed to compare characteristics associated with liver disease progression in diabetic patients diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD) versus those with MetALD. Materials and Methods: In this prospective study, 286 diabetic patients were followed for 12 months. All patients underwent transient elastography (TE) and ultrasound to assess hepatic steatosis. Participants were classified into MASLD and MetALD groups. The performance of fibrosis-4 index (FIB-4), and NAFLD fibrosis score (NFS) were also evaluated. Results: MASLD was diagnosed in 58.2% (167 patients), of whom 4.9% (7 patients) had TE values suggestive for liver cirrhosis. Among those with MetALD, 17.6% (21 patients) had TE values compatible with advanced fibrosis. MASLD subjects presented a slight decrease in liver fibrosis values from 6.58 ± 2.27 kPa to 6.03 ± 1.57 kPa in the 12 months. On the contrary, MetALD subjects had an increase of liver stiffness measurements (LSM) values from 11.83 ± 6.27 kPa to 12.24 ± 8.66 kPa. Conclusions: in diabetic patients, the coexistence of moderate alcohol intake and cardiometabolic risk factors (MetALD) is associated with more advanced liver fibrosis and impaired long-term glycemic control, compared to MASLD alone.Keywords
This publication has 29 references indexed in Scilit:
- Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohortJournal of Hepatology, 2024
- Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017–2020Clinical Gastroenterology and Hepatology, 2023
- New FIB-4 and NFS cutoffs to guide sequential non-invasive assessment of liver fibrosis by magnetic resonance elastography in NAFLDAnnals of Hepatology, 2022
- Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020Journal of Gastroenterology, 2021
- EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 updateJournal of Hepatology, 2021
- The times they are a-changin' (for NAFLD as well)Journal of Hepatology, 2020
- Repeated FIB-4 measurements can help identify individuals at risk of severe liver diseaseJournal of Hepatology, 2020
- Diagnosis and Treatment of Alcohol‐Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver DiseasesHepatology, 2019
- Determinants of fibrosis progression and regression in NASHJournal of Hepatology, 2018
- Alcohol consumption and the prevalence of metabolic syndrome: A meta-analysis of observational studiesAtherosclerosis, 2009